Last reviewed · How we verify
Choroidal retinal neovascularization — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Visudyne | VERTEPORFIN | Bausch Lomb Ireland | Photoenhancer [EPC] | 2000-01-01 | ||
| Lucentis | Lucentis | Santen Inc. | Vascular endothelial growth factor A | |||
| BYOOVIZ | RANIBIZUMAB-NUNA | SAMSUNG BIOEPIS CO LTD | Vascular endothelial growth factor A | |||
| Visudyne | Visudyne | Bayer |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bausch Lomb Ireland · 1 drug in Choroidal retinal neovascularization
- Bayer · 1 drug in Choroidal retinal neovascularization
- SAMSUNG BIOEPIS CO LTD · 1 drug in Choroidal retinal neovascularization
- Santen Inc. · 1 drug in Choroidal retinal neovascularization
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Choroidal retinal neovascularization:
- Choroidal retinal neovascularization treatment updates — RSS
- Choroidal retinal neovascularization treatment updates — Atom
- Choroidal retinal neovascularization treatment updates — JSON
Cite this brief
Drug Landscape (2026). Choroidal retinal neovascularization — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/choroidal-retinal-neovascularization. Accessed 2026-06-10.
Related
- Choroidal retinal neovascularization full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing